Genetics, artificial intelligence, new treatment protocols — pharmacology took a step in April from which there will be no turning back.
NeurogeneRx has entered clinical trials for a drug that adapts to a patient’s genetic profile in real time. It’s not magic, but a CRISPR-integrated nano-delivery formula.
No longer a “one pill fits all” — but a spot treatment that reads you better than a doctor.
The Ministry of Health has certified the CalmDose mobile app as a form of therapy for anxiety disorders. It is a program built on cognitive behavioral therapy that has pharmacological status.
What this means: now you can be “prescribed” not a pill, but an app that works with the patient’s neurobehavior.
In April, DeepMedLabs reported successfully formulating an anti-cancer drug in 5 months, instead of the usual 12-18. This was possible thanks to the use of a GPT-based model that calculates molecular interactions in minutes.
Trigger for investors: Medicine is entering an era where time is the new currency. Whoever shortens the cycle first will win.
The April resolution of the European Medical Agency was historic: microdoses of psilocybin are recommended for use as part of supervised therapy.
A trigger for the community: what was “psychonautics” yesterday is now a treatment supported by science.
The world has long lived in fear of superbugs that are immune to classic antibiotics. In April, a study published in The Lancet described a new molecule, PLX-0891, that can penetrate even the most resistant strains.
What this means: a weapon that can save millions has reappeared in the pharmaceutical world.
Pharmacology is no longer just about chemistry. It is a synthesis of data, bioengineering, psychology, and technology that together create a new model of health.
And if you still see medicine only as a “pill” — take a broader view: sometimes real treatment begins not in the pharmacy, but in the code.